Today’s Watch List : Vale S.A. (NYSE:VALE), GlaxoSmithKline plc (NYSE:GSK), Delta Air Lines, Inc. (NYSE:DAL), U.S. Silica Holdings, Inc. (NYSE:SLCA), MBII

Technology Stocks News 16

Shares of Brazilian metals and mining company Vale S.A. (NYSE:VALE) rose for the second consecutive day Tuesday after Brazil’s presidential election on Sunday resulted in a runoff to be held on October 26. Incumbent Dilma Rousseff received 41.59% of the votes, while challenger Aecio Neves received 33.54%. Vale S.A. (NYSE:VALE) belongs to Basic Materials sector. Its net profit margin is 1.40% and weekly performance is 1.44%. On last trading day company shares ended up $11.25. Vale S.A. (NYSE:VALE) distance from 50-day simple moving average (SMA50) is -12.00%.

GlaxoSmithKline Plc. (NYSE:GSK), the UK’s biggest drugmaker, will take a stake in the Japanese subsidiary of Aspen Pharmacare Holdings Ltd. as part of an alliance to boost commercial operations in the Asian country. GlaxoSmithKline plc (NYSE:GSK) shares decreased -2.10% in last trading session and ended the day at $44.81. GSK Gross Margin is 68.90% and its return on assets is 16.70%. GlaxoSmithKline plc (NYSE:GSK) quarterly performance is -15.45%.

Delta Air Lines, Inc. (NYSE:DAL), which lost a bid for two gates at Dallas Love Field to Virgin America last summer, will be able to continue to fly out of the airport through Jan. 6. Virgin America will take over the two gates on Oct. 13, but Southwest, which uses 16 gates at the airport, will share one with Delta. On 09 October, Delta Air Lines, Inc. (NYSE:DAL) shares decreased -3.16% and was closed at $33.71. DAL EPS growth in last 5 year was 21.50%. Delta Air Lines, Inc. (NYSE:DAL) year to date (YTD) performance is 23.43%.

U.S. Silica Holdings, Inc. (NYSE:SLCA) sport a Zacks Rank #1 (Strong Buy). U.S. Silica Holdings, Inc. (NYSE:SLCA) ended the last trading day at $48.95. Company weekly volatility is calculated as 6.98% and price to cash ratio as 14.56. U.S. Silica Holdings, Inc. (NYSE:SLCA) showed a weekly performance of -14.54%.

Pomerantz LLP has filed a class action lawsuit against Marrone Bio Innovations, Inc. (“Marrone” or the “Company”) (NASDAQ:MBII) and certain of its officers. The class action, filed in United States District Court, Eastern District of California, and docketed under 14-cv-02055, is on behalf of a class consisting of all persons or entities who purchased Marrone securities between March 6, 2014 and September 2, 2014, inclusive (the “Class Period”). Marrone Bio Innovations, Inc. (NASDAQ:MBII) shares decreased -4.18% in last trading session and ended the day at $2.29. MBII Gross Margin is 27.00% and its return on assets is -47.50%. Marrone Bio Innovations, Inc. (NASDAQ:MBII) quarterly performance is -78.70%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone